149 related articles for article (PubMed ID: 17063979)
1. Factors associated with healthcare utilization costs for statin therapy--a pilot study in Hong Kong.
Cheng CW; Chan JC; Tomlinson B; Woo KS; You JH
Int J Clin Pharmacol Ther; 2006 Oct; 44(10):484-8. PubMed ID: 17063979
[TBL] [Abstract][Full Text] [Related]
2. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease.
Cheng CW; Woo KS; Chan JC; Tomlinson B; You JH
Br J Clin Pharmacol; 2004 Nov; 58(5):528-35. PubMed ID: 15521901
[TBL] [Abstract][Full Text] [Related]
3. Initiation of statins after hospitalization for coronary heart disease.
Ye X; Gross CR; Schommer J; Cline R; Xuan J; St Peter WL
J Manag Care Pharm; 2007 Jun; 13(5):385-96. PubMed ID: 17605510
[TBL] [Abstract][Full Text] [Related]
4. Associations between statin adherence level, health care costs, and utilization.
Zhao Y; Zabriski S; Bertram C
J Manag Care Spec Pharm; 2014 Jul; 20(7):703-13. PubMed ID: 24967523
[TBL] [Abstract][Full Text] [Related]
5. Medical utilization and costs associated with statin adherence in Medicaid enrollees with type 2 diabetes.
Wu J; Seiber E; Lacombe VA; Nahata MC; Balkrishnan R
Ann Pharmacother; 2011 Mar; 45(3):342-9. PubMed ID: 21325098
[TBL] [Abstract][Full Text] [Related]
6. Attainment of normal lipid levels among patients on lipid-modifying therapy in Hong Kong.
Ambegaonkar B; Chirovsky D; Tse HF; Lau YK; Tomlinson B; Li SK; Yue CS; Wong TH; Choi MC; Tunggal P; Sazonov V
Adv Ther; 2012 May; 29(5):427-41. PubMed ID: 22562782
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of statin treatment for primary prevention in conditions of real-world adherence--estimates from the Finnish prescription register.
Aarnio E; Korhonen MJ; Huupponen R; Martikainen J
Atherosclerosis; 2015 Mar; 239(1):240-7. PubMed ID: 25618032
[TBL] [Abstract][Full Text] [Related]
8. Association between copayment and adherence to statin treatment initiated after coronary heart disease hospitalization: a longitudinal, retrospective, cohort study.
Ye X; Gross CR; Schommer J; Cline R; St Peter WL
Clin Ther; 2007 Dec; 29(12):2748-57. PubMed ID: 18201593
[TBL] [Abstract][Full Text] [Related]
9. Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong.
Lee VW; Ho IC; Chan WS; Tam KY; Lee KK
Am J Cardiovasc Drugs; 2008; 8(3):199-205. PubMed ID: 18533740
[TBL] [Abstract][Full Text] [Related]
10. Are high-risk hypertensive patients being prescribed concomitant statin therapy?: a retrospective cohort study.
Chapman RH; Petrilla AA; Berman L; Benner JS; Tang SS
Am J Cardiovasc Drugs; 2009; 9(5):299-308. PubMed ID: 19791839
[TBL] [Abstract][Full Text] [Related]
11. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
Kang HY; Ko SK; Liew D
Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
[TBL] [Abstract][Full Text] [Related]
12. Treating hyperlipidemia for the primary prevention of coronary disease. Are higher dosages of lovastatin cost-effective?
Perreault S; Hamilton VH; Lavoie F; Grover S
Arch Intern Med; 1998 Feb; 158(4):375-81. PubMed ID: 9487235
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment.
Pickin DM; McCabe CJ; Ramsay LE; Payne N; Haq IU; Yeo WW; Jackson PR
Heart; 1999 Sep; 82(3):325-32. PubMed ID: 10455083
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of raising HDL cholesterol by adding prolonged-release nicotinic acid to statin therapy in the secondary prevention setting: a French perspective.
Roze S; Ferrières J; Bruckert E; Van Ganse E; Chapman MJ; Liens D; Renaudin C
Int J Clin Pract; 2007 Nov; 61(11):1805-11. PubMed ID: 17850322
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein in 2005. Interview by Peter C. Block.
Ridker PM
J Am Coll Cardiol; 2005 Jul; 46(1):CS2-5. PubMed ID: 16007748
[TBL] [Abstract][Full Text] [Related]
16. Statins for cardiovascular prevention according to different strategies: a cost analysis.
Ito MK; Nanchen D; Rodondi N; Paccaud F; Waeber G; Vollenweider P; Marques-Vidal P
Am J Cardiovasc Drugs; 2011; 11(1):33-44. PubMed ID: 21265581
[TBL] [Abstract][Full Text] [Related]
17. Case selection for statins was similar in two Canadian provinces: BC and Ontario.
Paterson JM; Carney G; Anderson GM; Bassett K; Naglie G; Laupacis A;
J Clin Epidemiol; 2007 Jan; 60(1):73-8. PubMed ID: 17161757
[TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering effect of preoperative statin therapy on postoperative major adverse cardiac events after coronary artery bypass surgery.
Thielmann M; Neuhäuser M; Marr A; Jaeger BR; Wendt D; Schuetze B; Kamler M; Massoudy P; Erbel R; Jakob H
J Thorac Cardiovasc Surg; 2007 Nov; 134(5):1143-9. PubMed ID: 17976441
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
Davies GM; Vyas A; Baxter CA
J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
[TBL] [Abstract][Full Text] [Related]
20. Impact of prescription size on statin adherence and cholesterol levels.
Batal HA; Krantz MJ; Dale RA; Mehler PS; Steiner JF
BMC Health Serv Res; 2007 Oct; 7():175. PubMed ID: 17961256
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
